BIOMAT Database Logo BIOMAT Database Logo

[Clinical studies on the effect of a new oral antidiabetic agent Glybenclamide (HB 419)]. 1969

H Schmitt, and H Höhler, and H Daweke, and K Jahnke

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H Schmitt, and H Höhler, and H Daweke, and K Jahnke
[Glybenclamide (HB 419): a new oral antidiabetic agent of the sulfonylurea group].
April 1969, Deutsche medizinische Wochenschrift (1946),
H Schmitt, and H Höhler, and H Daweke, and K Jahnke
A clinical trial of glybenclamide (HB-419): a new oral hypoglycemic agent.
May 1970, Applied therapeutics,
H Schmitt, and H Höhler, and H Daweke, and K Jahnke
[Antimicrobial effect of the new oral antidiabetic HB 419].
August 1969, Arzneimittel-Forschung,
H Schmitt, and H Höhler, and H Daweke, and K Jahnke
[Effect of HB 419--a new oral antidiabetic--on fat metabolism].
August 1969, Arzneimittel-Forschung,
H Schmitt, and H Höhler, and H Daweke, and K Jahnke
Clinical trial with HB 419 (Glybenclamide).
January 1970, Bulletin of the Calcutta School of Tropical Medicine,
H Schmitt, and H Höhler, and H Daweke, and K Jahnke
[Clinical report of the experience in therapy with oral antidiabetic agent HB 419].
September 1969, Wiener klinische Wochenschrift,
H Schmitt, and H Höhler, and H Daweke, and K Jahnke
[Clinical experiences with oral antidiabetic HB 419 (glibenclamide)].
August 1969, Arzneimittel-Forschung,
H Schmitt, and H Höhler, and H Daweke, and K Jahnke
[HB 419, a new oral antidiabetic; administration to the aged].
September 1969, Wiener medizinische Wochenschrift (1946),
H Schmitt, and H Höhler, and H Daweke, and K Jahnke
[Pharmacology of HB 419, a new strongly effective oral antidiabetic].
August 1969, Arzneimittel-Forschung,
H Schmitt, and H Höhler, and H Daweke, and K Jahnke
Glibenclamide (HB 419): a new oral antidiabetic of sulphonylurea type.
August 1969, German medical monthly,
Copied contents to your clipboard!